Prostate Cancer

Prostate Cancer

Biochemical Relapse Free Survival of Patients With Low-Risk Prostate Cancer by Treatment Typeᵃ (N = 2300)

1996-2019

Number at Risk5 Years10 Years15 Years
External Beam Radiotherapy (N = 505)96.0% (345)85.6% (143)66.4% (26)
Low-Dose-Rate Brachytherapy (N = 1795)95.3% (856)85.1% (190)68.3% (23)

EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Biochemical Relapse Free Survival of Patients With Favorable Intermediate-Risk Prostate Cancer by Treatment Typeᵃ (N = 1793)

1996-2019

Number at Risk5 Years10 Years15 Years
External Beam Radiotherapy (N = 384)89.1% (223)74.7% (99)55.9% (8)
Low-Dose-Rate Brachytherapy (N = 1409)92.6% (479)77.7% (66)58.3% (7)

EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Biochemical Relapse Free Survival of Patients With Unfavorable Intermediate Risk Prostate Cancer by Treatment Typeᵃ (N = 1093)

1996-2019

Number at Risk5 Years10 Years15 Years
External Beam Radiotherapy (N = 327)77.8% (159)60.2% (60)40.9% (12)
Low-Dose-Rate Brachytherapy (N =766)80.1% (203)52.3% (15)NA

EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Biochemical Relapse Free Survival of Patients With High-Risk Prostate Cancer by Treatment Typeᵃ (N = 998)

1996-2019

Number at Risk5 Years10 Years15 Years
External Beam Radiotherapy (N = 623)71.0% (282)46.7% (92)35.5% (11)
Low-Dose-Rate Brachytherapy (N = 375)65.0% (97)42.2% (11)NA

EBRT= External Beam Radiotherapy, LDRBT = Low-Dose-Rate Brachytherapy

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Cumulative Mortality Due to Prostate Cancer of Patients With Low-Risk Prostate Cancer by Treatment Typeᵃ (N= 2300)

1996-2019

Number at Risk5 Years10 Years15 Years
External Beam Radiotherapy (N = 505)0.87% (396)1.62% (226)4.84% (63)
Low-Dose-Rate Brachytherapy (N = 1795)0.24% (1005)1.62% (293)2.88% (55)

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Cumulative Mortality Due to Prostate Cancer of Patients With Favorable Intermediate Risk Prostate Cancer by Treatment Typeᵃ (N= 1793)

1996-2019

Number at Risk5 Years10 Years15 Years
External Beam Radiotherapy (N = 384)0.88% (280)2.66% (160)6.44% (26)
Low-Dose-Rate Brachytherapy (N = 1409)0.38% (559)1.85% (118)5.78% (20)

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Cumulative Mortality Due to Prostate Cancer of Patients With Unfavorable Intermediate Risk Prostate Cancer by Treatment Typeᵃ (N= 1093)

1996-2019

Number at Risk5 Years10 Years15 Years
External Beam Radiotherapy (N = 327)3.33% (228)6.75% (127)10.95% (36)
Low-Dose-Rate Brachytherapy (N = 766)0.75% (297)3.11% (54)7.36% (4)

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.

Cumulative Mortality Due to Prostate Cancer of Patients With High-Risk Prostate Cancer by Treatment Typeᵃ (N= 998)

1996-2019

Number at Risk5 Years10 Years15 Years
External Beam Radiotherapy (N = 623)5.52% (438)13.41% (240)18.67% (56)
Low-Dose-Rate Brachytherapy (N = 375)4.07% (173)8.56% (36)8.56% (7)

ᵃNational Comprehensive Cancer Network (NCCN). Prostate Cancer. NCCN Clinical Practice Guidelines in Oncology. V.2.2007. Fort Washington, PA: NCCN; 2007.